Уноси

Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications. (2020-03)

N. Miljković, B. Godman, M. Kovačević, P. Polidori, L. Tzimis, T. Hoppe-Tichy, M. Saar, I. Antofie, L. Horvath, T. De Rijdt, R. Vida, E. Kkolou, D. Preece, B. Tubić, J. Peppard, A. Martinez, C. Garcia Yubero, R. Haddad, D. Rajinac, P. Zelić, H. Jenzer, F. Tartar, G. Gitler, M. Jeske, M. Davidescu, G. Beraud, D. Kuruc Poje, K. Sakstrup Haag, H. Fischer, I. Sviestina, G. Ljubojević, A. Markestad, V. Vujić-Aleksić, L. Nežić, A. Crkvenčić, J. Linnolahti, B. Ašanin, N. Duborija-Kovačević, T. Bochenek, I. Huys, B. Miljković, Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications., Frontiers in Pharmacology, Vol. 11, No. 357, Mar, 2020
Klinički značajne interakcije opioidnih i neopioidnih analgetika (Clinically important drug interactions of opioid and non-opioid analgetics) (2018)

S. Vezmar Kovačević, K. Vučićević, V. Topić-Vučenović, Z. Rajkovača, B. Miljković, Klinički značajne interakcije opioidnih i neopioidnih analgetika (Clinically important drug interactions of opioid and non-opioid analgetics), Arhiv za farmaciju, Vol. 68, No. 6, pp. 1071 - 1083, 2018
Izazovi i stavovi o doziranju radioaktivnog joda u terapiji benignih oboljenja štitne žlijezde (2018-04)

V. Topić Vučenović, Z. Rajkovača, S. Vezmar Kovačević, B. Miljković, K. Vučićević, Izazovi i stavovi o doziranju radioaktivnog joda u terapiji benignih oboljenja štitne žlijezde, Arhiv za farmaciju, Vol. 67, pp. 333 - 344, Apr, 2018
Investigation of factors influencing radioiodine (131I) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach (2018-05)

В. Топић Вученовић, Z. Rajkovača, D. Jelić, D. Stanimirović, G. Vuleta, B. Miljković, K. Vučićević, Investigation of factors influencing radioiodine (131I) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach, EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, Vol. 74, No. 8, pp. 1037 - 1045, May, 2018
Klinički značajne interakcije opioidnih i neopioidnih analgetika (Clinically important drug interactions of opioid and non-opioid analgetics) (2018-12)

S. Vezmar Kovačević, K. Vučićević, V. Topić Vučenović, Z. Rajkovača, B. Miljković, Klinički značajne interakcije opioidnih i neopioidnih analgetika (Clinically important drug interactions of opioid and non-opioid analgetics), Arhiv za farmaciju, Vol. 68, No. 6, pp. 1071 - 1083, Dec, 2018
The Effect of Hypoalbuminemia on the Therapeutic Concentration and Dosage of Vancomycin in Critically Ill Septic Patients in Low-Resource Countries (2019)

T. Kovačević, B. Miljkovic, M. Mikov, S. Stojisavljević-Šatara, S. Dragic, D. Momcicevic, P. Kovačević, The Effect of Hypoalbuminemia on the Therapeutic Concentration and Dosage of Vancomycin in Critically Ill Septic Patients in Low-Resource Countries, DOSE-RESPONSE, pp. 0 - 0, 2019
The Effect of Hypoalbuminemia on the Therapeutic Concentration and Dosage of Vancomycin in Critically Ill Septic Patients in Low-Resource Countries (2019-05)

T. Kovačević, B. Miljkovic, M. Mikov, S. Stoisavljević-Šatara, S. Dragić, D. Momčičević, P. Kovačević, The Effect of Hypoalbuminemia on the Therapeutic Concentration and Dosage of Vancomycin in Critically Ill Septic Patients in Low-Resource Countries, DOSE-RESPONSE, Vol. 17, No. 2, pp. 1 - 6, May, 2019
Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients (2020)

T. Kovačević, B. Miljkovic, P. Kovačević, S. Dragic, D. Momcicevic, S. Avram, M. Jovanovic, K. Vucicevic, Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients, JOURNAL OF CRITICAL CARE, pp. 116 - 121, 2020
Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients (2020-06)

T. Kovačević, B. Miljkovic, P. Kovačević, S. Dragić, D. Momčičević, S. Avrama, M. Jovanovic, K. Vucicevic, Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients, JOURNAL OF CRITICAL CARE, Vol. 55, pp. 116 - 121, Jun, 2020
Impact of pharmacist's intervention on decreasing erlotinib interactions in the treatment of lung cancer patients in low resource settings (2021-03)

T. Kovačević, S. Vezmar Kovacevic, M. Stanetić, P. Kovačević, B. Miljkovic, Impact of pharmacist's intervention on decreasing erlotinib interactions in the treatment of lung cancer patients in low resource settings, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, Vol. 27, No. 2, pp. 350 - 358, Mar, 2021
Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice (2021-08)

M. Roganović, A. Homšek, M. Jovanović, V. Topić Vučenović, M. Ćulafić, B. Miljković, K. Vučićević, Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice, Arhiv za farmaciju, Vol. 71, No. 4, pp. 336 - 353, Aug, 2021
Nonlinear mixed effects modelling approach for investigation of 131I in patients with benign thyroid disease (2017)

V. Topić Vučenović, k. vučičević, z. rajkovača, d. stanimirović, D. Jelić, g. vuleta, b. miljković, Nonlinear mixed effects modelling approach for investigation of 131I in patients with benign thyroid disease, 2017
Nonlinear mixed effects modelling approach for investigation of 131I kinetics in patients with benign thyroid disease (2017-06)

V. Topić Vučenović, K. Vučićević, Z. Rajkovača, D. Stanimirović, G. Vuleta, D. Jelić, B. Miljković, Nonlinear mixed effects modelling approach for investigation of 131I kinetics in patients with benign thyroid disease, Jun, 2017
Investigation of influence of anti-thyroid drug discontinuation time on 131I biokinetics in patients with benign thyroid disease (2017-10)

V. Topić, K. Vučićević, Z. Rajkovača, D. Stanimirović, G. Vuleta, D. Jelić, B. Miljković, Investigation of influence of anti-thyroid drug discontinuation time on 131I biokinetics in patients with benign thyroid disease, Eur J Nucl Med Mol Imaging. 2017; 44 (Suppl 2), pp. S809 - S809, Oct, 2017
Prediction of the radioiodine therapy outcomes in patients with benign thyroid disease based on pre-therapeutic dosimetry (2018-09)

V. Topić Vučenović, D. Jelić, Z. Rajkovača, B. Miljković, K. Vučićević, Prediction of the radioiodine therapy outcomes in patients with benign thyroid disease based on pre-therapeutic dosimetry, Kongres nuklearne medicine Srbije sa međunarodnim učešćem 2018, Program i zbornik sažetaka, pp. 135 - 135, Sep, 2018
Population exposure-response model of 131I in patients with benign thyroid disease (2021-10)

V. Topić Vučenović, Z. Rajkovača, D. Jelić, D. Stanimirović, M. Mikov, B. Miljković, K. Vučićević, Population exposure-response model of 131I in patients with benign thyroid disease, EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, Vol. 165, pp. 105942 - 105942, Oct, 2021
The influence of biologically effective dose (BED) on the 131I therapy response in patients with benign thyroid disease – nonlinear mixed effect modelling approach (2021-01)

V. Topić Vučenović, Z. Rajkovača, D. Jelić, D. Stanimirović, M. Mikov, B. Miljković, K. Vučićević, The influence of biologically effective dose (BED) on the 131I therapy response in patients with benign thyroid disease – nonlinear mixed effect modelling approach, https://www.paganz.org/abstracts/the-influence-of-biologically-effective-dose-bed-on-the-131i-therapy-response-in-patients-with-benign-thyroid-disease-nonlinear-mixed-effect-modelling-approach/, Jan, 2021

Уноси

Prospective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications. (2020-03)

Klinički značajne interakcije opioidnih i neopioidnih analgetika (Clinically important drug interactions of opioid and non-opioid analgetics) (2018)

Izazovi i stavovi o doziranju radioaktivnog joda u terapiji benignih oboljenja štitne žlijezde (2018-04)

Investigation of factors influencing radioiodine (131I) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach (2018-05)

Klinički značajne interakcije opioidnih i neopioidnih analgetika (Clinically important drug interactions of opioid and non-opioid analgetics) (2018-12)

The Effect of Hypoalbuminemia on the Therapeutic Concentration and Dosage of Vancomycin in Critically Ill Septic Patients in Low-Resource Countries (2019)

The Effect of Hypoalbuminemia on the Therapeutic Concentration and Dosage of Vancomycin in Critically Ill Septic Patients in Low-Resource Countries (2019-05)

Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients (2020)

Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients (2020-06)

Impact of pharmacist's intervention on decreasing erlotinib interactions in the treatment of lung cancer patients in low resource settings (2021-03)

Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice (2021-08)

Nonlinear mixed effects modelling approach for investigation of 131I in patients with benign thyroid disease (2017)

Nonlinear mixed effects modelling approach for investigation of 131I kinetics in patients with benign thyroid disease (2017-06)

Investigation of influence of anti-thyroid drug discontinuation time on 131I biokinetics in patients with benign thyroid disease (2017-10)

Prediction of the radioiodine therapy outcomes in patients with benign thyroid disease based on pre-therapeutic dosimetry (2018-09)

Population exposure-response model of 131I in patients with benign thyroid disease (2021-10)

The influence of biologically effective dose (BED) on the 131I therapy response in patients with benign thyroid disease – nonlinear mixed effect modelling approach (2021-01)